Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

NCT01156415 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

837

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: AGO178
DRUG: AGO178

Sponsor

Novartis Pharmaceuticals